{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:46:31Z","timestamp":1785321991633,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00428-024-03890-w","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T08:20:23Z","timestamp":1723191623000},"page":"519-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High success rate of first proficiency testing for RET fusions and RET mutations in lung and thyroid cancer samples by various methods"],"prefix":"10.1007","volume":"485","author":[{"given":"Udo","family":"Siebolts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pappesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Dietmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Haak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Ilm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Kalbourtzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kazdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Schorle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Utpatel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Merkelbach-Bruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"issue":"4","key":"3890_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2159-8290.CD-19-1116","volume":"10","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Cote GJ (2020) Advances in targeting RET-dependent cancers. Cancer Discov 10(4):498\u2013505. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1116","journal-title":"Cancer Discov"},{"issue":"11","key":"3890_CR2","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.19.02551","volume":"38","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F (2020) State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol 38(11):1209\u20131221. https:\/\/doi.org\/10.1200\/JCO.19.02551","journal-title":"J Clin Oncol"},{"issue":"5","key":"3890_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","volume":"17","author":"D Salvatore","year":"2021","unstructured":"Salvatore D, Santoro M, Schlumberger M (2021) The importance of the RET gene in thyroid cancer and therapeutic implications. Nat Rev Endocrinol 17(5):296\u2013306. https:\/\/doi.org\/10.1038\/s41574-021-00470-9","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"3890_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simoes M, Tallini G, Mete O (2022) Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 33(1):27\u201363. https:\/\/doi.org\/10.1007\/s12022-022-09707-3","journal-title":"Endocr Pathol"},{"issue":"1","key":"3890_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/his.13373","volume":"72","author":"J Guilmette","year":"2018","unstructured":"Guilmette J, Nose V (2018) Hereditary and familial thyroid tumours. Histopathology 72(1):70\u201381. https:\/\/doi.org\/10.1111\/his.13373","journal-title":"Histopathology"},{"issue":"3","key":"3890_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","volume":"15","author":"A Drilon","year":"2018","unstructured":"Drilon A, Hu ZI, Lai GGY, Tan DSW (2018) Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol 15(3):151\u2013167. https:\/\/doi.org\/10.1038\/nrclinonc.2017.175","journal-title":"Nat Rev Clin Oncol"},{"key":"3890_CR7","unstructured":"FDA (2022) RETEVMO\u00ae (selpercatinib) capsules, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213246s008lbl.pdf Accessed 2023"},{"key":"3890_CR8","unstructured":"EMA (2023) Retsevmo. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/retsevmo Accessed 2023"},{"issue":"3","key":"3890_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","volume":"32","author":"C Belli","year":"2021","unstructured":"Belli C, Penault-Llorca F, Ladanyi M, Normanno N, Scoazec JY, Lacroix L, Reis-Filho JS, Subbiah V, Gainor JF, Endris V, Repetto M, Drilon A, Scarpa A, Andre F, Douillard JY, Curigliano G (2021) ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol 32(3):337\u2013350. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.021","journal-title":"Ann Oncol"},{"issue":"3","key":"3890_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00428-020-02928-z","volume":"478","author":"K Dufraing","year":"2021","unstructured":"Dufraing K, Fenizia F, Torlakovic E, Wolstenholme N, Deans ZC, Rouleau E, Vyberg M, Parry S, Schuuring E, Dequeker EMC, ABSL IQ (2021) Biomarker testing in oncology - Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL. Virchows Arch 478(3):553\u2013565. https:\/\/doi.org\/10.1007\/s00428-020-02928-z","journal-title":"Virchows Arch"},{"issue":"1","key":"3890_CR11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12909-023-04396-w","volume":"23","author":"P Lazure","year":"2023","unstructured":"Lazure P, Sireci A, Subbiah V, Murray S, Grohe C, Sherman SI, Kelly E, Bubach P, Peloquin S (2023) Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study. BMC Med Educ 23(1):410. https:\/\/doi.org\/10.1186\/s12909-023-04396-w","journal-title":"BMC Med Educ"},{"key":"3890_CR12","doi-asserted-by":"publisher","unstructured":"Kahles A, Goldschmid H, Volckmar AL, Ploeger C, Kazdal D, Penzel R, Budczies J, Kempny G, Kazmierczak M, Flechtenmacher C, Baretton G, Weichert W, Horst D, Klauschen F, Gassner UM, Bruggemann M, Vogeser M, Schirmacher P, Stenzinger A (2023) Structure and content of the EU-IVDR: current status and implications for pathology. Pathologie, Heidelb, p 1\u201313. https:\/\/doi.org\/10.1007\/s00292-022-01176-z","DOI":"10.1007\/s00292-022-01176-z"},{"issue":"1","key":"3890_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s43441-021-00323-7","volume":"56","author":"F Spitzenberger","year":"2022","unstructured":"Spitzenberger F, Patel J, Gebuhr I, Kruttwig K, Safi A, Meisel C (2022) Laboratory-developed tests: design of a regulatory strategy in compliance with the International State-of-the-Art and the Regulation (EU) 2017\/746 (EU IVDR [In Vitro Diagnostic Medical Device Regulation]). Ther Innov Regul Sci 56(1):47\u201364. https:\/\/doi.org\/10.1007\/s43441-021-00323-7","journal-title":"Ther Innov Regul Sci"},{"issue":"4","key":"3890_CR14","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1210\/clinem\/dgaa913","volume":"106","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wu S, Zhou L, Guo Y, Zeng X (2021) Pitfalls in RET fusion detection using break-apart FISH probes in papillary thyroid carcinoma. J Clin Endocrinol Metab 106(4):1129\u20131138. https:\/\/doi.org\/10.1210\/clinem\/dgaa913","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3890_CR15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jtho.2021.01.1619","volume":"16","author":"T Radonic","year":"2021","unstructured":"Radonic T, Geurts-Giele WRR, Samsom KG, Roemen G, von der Thusen JH, Thunnissen E, Meijssen IC, Sleddens H, Dinjens WNM, Boelens MC, Weijers K, Speel EJM, Finn SP, O\u2019Brien C, van Wezel T, Cohen D, Monkhorst K, Roepman P, Dubbink HJ (2021) RET fluorescence in situ hybridization analysis is a sensitive but highly unspecific screening method for RET fusions in lung cancer. J Thorac Oncol 16(5):798\u2013806. https:\/\/doi.org\/10.1016\/j.jtho.2021.01.1619","journal-title":"J Thorac Oncol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03890-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-024-03890-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03890-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T09:05:16Z","timestamp":1726823116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-024-03890-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3890"],"URL":"https:\/\/doi.org\/10.1007\/s00428-024-03890-w","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"assertion":[{"value":"26 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Udo Siebolts and Daniel Kazdal received honoraria from Eli Lilly and Company. Thomas Krause is an employee and shareholder of Eli Lilly and Company. Other authors have no competing interests to declare. Roberto Pappesch received honoraria from ArcherDX. Udo Siebolts received financial support for participation in advisory boards from Sanofi and MSD and honoraria from AstraZeneca. Nils Hartmann received honoraria from Qiagen. Katharina Ilm received support for participation in the advisory board from Amgen GmbH. Daniel Kazdal received honoraria from Agilent, AstraZeneca, BMS, Illumina, Incyte, Pfizer, and Takeda. Hubert Schorle received a travel grant from Andronet COST Action EU framework. Sabine Merckelbach-Bruse received grants from Roche and QuIP (Quality Initiative Pathology), consulting fees from AstraZeneca, and honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Discovery Life Science, Janssen, Menarini, Merck, Novartis, and QuIP. Other authors have no financial interests to disclose. Kirsten Utpatel participated in an advisory board with Roche. Other authors have no non-financial interests to disclose. Thomas Krause, the author of this manuscript, is an employee of Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}